. 2018 Oct 10;9(21):3886–3893. doi: 10.7150/jca.27960

Table 3.

Relationships of genotypic distribution of receptor for advanced glycation end products genetic varivants rs184003 and rs1800624 with clinicopathological parameters of the patients with invasive cancer of uterine cervix.

	rs184003				rs1800624
Variable	GG^b	GT/ TT	p value	ORs (95% CIs)	TT^b	TA/ AA	p value	ORs (95% CIs)
Clinical stage			0.129				0.103
stage I^b	49	17		1.00	50	16		1.00
≥ stage II	26	17		1.88 (0.76-4.65)	38	5		0.41 (0.11-1.32)
Pathologic type			0.968				0.759
squamous cell carcinoma^b	62	28		1.00	73	17		1.00
adenocarcinoma	13	6		1.02 (0.29-3.26)	15	4		1.15 (0.25-4.24)
Cell grading			0.337				0.034^c
well (grade 1)^b	17	5		1.00	14	8		1.00
moderate & poor (grades 2/3)	58	29		1.70 (0.53-6.46)	74	13		0.31 (0.10-1.03)
Stromal invasion depth			0.596				0.175
≤10 mm^b	45	18		1.00	48	15		1.00
>10 mm	30	15		1.25 (0.50-3.09)	39	6		0.49 (0.14-1.51)
Tumor diameter^b			0.312				0.092
≤ 4cm	48	18		1.00	50	16		1.00
>4cm	28	16		1.52 (0.62-3.73)	39	5		0.40 (0.11-1.28)
Parametrium			0.418				0.023^c
no invasion^b	55	22		1.00	58	19		1.00
invasion	21	12		1.43 (0.54-3.66)	31	2		0.20 (0.02-0.92)
Vagina			0.279				0.153
no invasion^b	60	24		1.00	66	18		1.00
invasion	15	10		1.67 (0.58-4.61)	23	2		0.32 (0.03-1.52)
Pelvic lymph node			0.848				0.035^c
no metastasis^b	55	24		1.00	60	19		1.00
metastasis	21	10		1.09 (0.40-2.88)	29	2		0.22 (0.02-1.01)

Statistical analyses: chi-square or Fisher's exact tests, ^cp<0.05

^aSome clinicopathological data could not be obtained from the patients with cervical invasive cancer due to incomplete medical charts or records.

^bAs a reference. ORs, odds ratios; 95% CIs, 95% confidence intervals.